Fractyl Health Inc. Common Stock (GUTS)

FairStock Score: 10/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I begin with proven earning power, and here there is very little. In fiscal 2024, the year ended 2024-12-31, revenue was $93,000. In fiscal 2023, revenue was $120,000. Fiscal 2025 revenue is not available in the filed figures. Meanwhile, the company lost $68.7M in fiscal 2024 and $141.0M in fiscal 2025. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$25.5M and diluted EPS was -$0.16. That is not a business with a moat or pricing power yet; it is a research-stage enterprise whose outcome depends on clinical and regulatory events for Revita and Rejuva. Financial health is poor on the supplied FairStock calculations: debt-to-equity 2.84, Altman Z-Score -5.70, Piotroski F-Score 2/9, ROE -778.33%, ROCE -74.57%. Trailing free cash flow is -$82.4M, a -12.9% FCF yield on the $640.7M market cap. Valuation offers no Graham-style comfort: at the 2026-10-13 close of $4.03, P/B is 14.35 and P/E is -4.42. The FairStock Score is 10/100, and the Lynch category is none because the company lost money in each of the last three years. The one positive filed quarter is fiscal Q1 2026, ended 2026-03-31, with net income of $9.2M and diluted EPS of $0.06, but that was followed by a large loss. I see speculative optionality, not a durable value investment.

In plain English: Fractyl Health is working on treatments for type 2 diabetes and obesity. The business looks weak today: it has almost no sales, is losing a lot of money, and is burning cash. Compared with those numbers, the stock price looks expensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer